Monitor for additional selling in the next 30 days; isolated small sales by executives are common and typically not predictive, but pattern changes could signal shifting sentiment.
DYN drugs
DYN drug pipeline →- ▲ z-rostudirsen 8/10 Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing · PDUFA date Jan 21, 2027
- ◆ z-basivarsen 7/10 Phase 3 (HARMONIA confirmatory trial, initiated March 2026); Phase 1/2 registrational cohort (ACHIEVE) fully enrolled · BLA filing Q3 2027
- ● DYNE-302 2/10
- All DYN drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 5 $15.20entry
- T+1 · 9mo ago −2.24%α −0.92% · $14.86
- T+5 · 8mo ago +18.82%α +21.05% · $18.06
- T+20 · 8mo ago +23.95%α +27.74% · $18.84
- T+60 · 6mo ago +22.57%α +11.27% · $18.63
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two top executives at Dyne Therapeutics, the CEO and Chief Medical Officer, sold shares in a coordinated open-market transaction totaling approximately $54,200. The sales represent a routine divestiture with minimal dollar value relative to the company's $2.5B market cap.
Key Financial Metrics
Key Facts
- CEO John Cox sold 2,732 shares for $40,706.80 in an open-market transaction.
- Chief Medical Officer Douglas Kerr sold 904 shares for $13,469.60, also via open-market sale.
- Total value of insider sales: $54,176.40 across two C-suite executives.
- Sales occurred on the same day at $14.90 per share, within normal trading activity.
- Total value represents only 0.002% of Dyne Therapeutics' $2.5B market capitalization.
Financial Impact
$54,176 in total open-market sales by C-suite executives
Risk Factors
- Perception of insider confidence may be slightly weakened, though the dollar amount is negligible.
- Concurrent sales by CEO and CMO could raise questions if followed by negative news or lack of progress in clinical programs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (2 trades, 7d window) | cluster-DYN-1772831364149 |
Track record
54 reports on DYN
12 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 15 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers